Chief Science Officer
Dr. Steven Greco, Ph.D., is the Chief Science Officer for Okyanos Global Health and the Okyanos Innovation Center, and serves as Director of Research for Rejenevie Therapeutics. Formally trained as a stem cell biologist, over the past 14 years Dr. Greco has contributed original research publications within the fields of regenerative and translational medicine. His expanding expertise has covered various regenerative research areas, including adipose (fat) tissue-derived stem cells, and he participated and managed oncology research at Rutgers University-particularly in the areas of stem cells and aging, breast cancer and brain tumors. His studies have primarily focused on human adult bone marrow stem cells, namely hematopoietic and mesenchymal stem cells. Dr. Greco’s current research focuses on aging biology, specifically approaches to restore function to the aging immune system.
Dr. Greco previously served as Vice President of Research and Development for Neurotez Inc., a company focused on Alzheimer’s disease drug discovery, early-stage development and basic research. During this tenure, Dr. Greco oversaw numerous aspects of drug development, from preclinical studies to cGMP manufacturing of a biologic to organization of IND-enabling studies and clinical trial design for FDA submission.
He received both his Ph.D. in stem cell biology and M.S. in biomedical sciences from Rutgers University and his B.A. from Cornell University, where he studied animal physiology. Dr. Greco is a contributing author on over 55 research publications and 9 US and international patents.